Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2004

01-04-2004 | Special Article

Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data

Authors: E. Vidor, R. Dumas, V. Porteret, F. Bailleux, K. Veitch

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2004

Login to get access

Abstract

Inactivated hepatitis A vaccines were developed in the 1980s and were introduced during the early 1990s. The Aventis Pasteur (AvP) inactivated hepatitis A virus antigen is used in several different vaccine formulations licensed for adults and children. Presented here are the immunogenicity results compiled from 37 clinical trials performed in 20 different countries between 1991 and 2001 in which these vaccines were administered to adults (16 years of age and over), children (aged 12 months–17 years), and infants (younger than 12 months). The accumulated clinical experience with these hepatitis A virus-containing vaccines demonstrates the excellent immunogenicity of this antigen in a wide range of situations. As with other licensed inactivated hepatitis A vaccines, immunological priming is achieved in virtually all vaccinees after a single-dose primary immunization, and it may be reinforced by a booster vaccination administered 6–36 months after the primary vaccination.
Literature
1.
André FE, d’Hondt E, Delem AD, Safary A (1992) Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine—rationale and summary of findings. Vaccine 10 (Suppl 1):160–168
2.
3.
Vidor E, Fritzell B, Plotkin, S (1996) Clinical development of a new inactivated hepatitis A vaccine. Infection 24:447–458PubMed
4.
Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glück R, Herzog C (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15:1209–1213CrossRefPubMed
5.
Feinstone SM, Gust ID (1998) Hepatitis A vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines. WB Saunders, Philadelphia, pp 650–671
6.
Ambrosch F, Wiedermann G, André FE, Delem AD, Gregor H, Hofmann H, d’Hondt E, Kundi M, Wynen J, Kunz C (1994) Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 44:452–456PubMed
7.
Overbosh D, Peyron F, Picot N, Varichon JP (2001) Immunogenicity and safety of a combined typhoid fever and hepatitis A vaccine: a comparison of the combined vaccine in a dual-chamber syringe presentation versus the monovalent vaccines. In: Program and abstracts of the 7th International Conference on Travel Medicine. Abstract no. 63
8.
Loebermann M, Kollaritsch H, Chappey O, Chambonneau L, Dumas R, Lafrenz M (2001) Immunogenicity and safety of a combined typhoid fever and hepatitis A vaccine in healthy adults. In: Program and abstracts of the 7th International Conference on Travel Medicine. Abstract no. 64
9.
Van Hoecke C, Lebacq E, Beran J, Prymula R, Collard F (1998) Concomitant vaccination against hepatitis A and typhoid fever. J Trav Med 5:116–120
10.
Piazza M, Safary A, Vegnente A, Soncini R, Pensati P, Sardo M, Orlando R, Tosone G, Picciotto L (1999) Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in childhood vaccination programme. Vaccine 17:585–588CrossRefPubMed
11.
Shapiro CN, Letson GW, Kuehn D, Welty TK, Krause D, Lambert S, Margolis HS (1995) Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. H-61
12.
Lieberman JM, Marcy SM, Partridge J, Ward J (1998) Evaluation of a hepatitis A vaccine in infants: effect of maternal antibodies on the antibody response. In: Program and abstracts of the 36th Infectious Diseases Society of America annual meeting. Abstract no. 76
13.
Troisi CL, Hollinger FB, Krause DS, Pickering LK (1997) Immunization of seronegative infants with hepatitis A vaccine (HAVRIX): a comparative study of two dosing schedules. Vaccine 15:1613–1617CrossRefPubMed
14.
Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, Thoelen S, Safary A, Ashkenazi S (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Ped Infect Dis J 19:1045–1052CrossRef
15.
Lopez EL, Contrini MM, Xifro M, Del C, Ceccoli SC, Cattaneo MA, Zambrano B, Dumas R, Rouyrre N, Weber F (2002) Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. In: Program and abstracts of the 3rd World Congress of Pediatric Infectious Diseases. Abstract no. 25
16.
Lagos R, Munoz A, Dumas R, Pichon S, Zambrano B, Levine M, Vidor E (2003) Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. Vaccine 21:3730–3733CrossRefPubMed
17.
Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, Shouval D, Ellerbeck EF, Block SL, Bishop RP, Wiens B, Schwartz SW, Lewis JA, Sitrin RD, Provost PJ, Miller WJ, Ryan JL (1993) Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 18 (Suppl 2):51–55
18.
Vidor E, Fanget B, Montagnon B, Flehmig B (1993) Preliminary results of the clinical development of a highly purified inactivated hepatitis A vaccine. In: Spiess H (ed) Immunprophylaxe gegen Hepatitis A. Deutsches Grünes Kreuz, Marburg, pp 115–166
19.
Garin D, Vidor E, Wallon M, Fanget B, Brasseur P, Delolme H, Caron F, Mojon M, Gravey A, Humbert G, Flehmig B, Peyron F (1995) Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 13:220–224CrossRefPubMed
20.
Zanetti A, Pregliasco F, Andreassi A, Pozzi A, Vigano P, Cargnel A, Briantais P, Vidor E (1997) Does immunoglobulin interfere with the immunogenicity to Pasteur Mérieux inactivated hepatitis A vaccine? J Hepatol 26:25–30CrossRefPubMed
21.
Walter EB, Hornick RB, Poland GA, Tucker R, Bland CL, Clements DA, Rhamstine CC, Jacobson RM, Brown L, Gress JO, Harris KE, Wiens BL, Nalin DR (1999) Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. Vaccine 17:1468–1473CrossRefPubMed
22.
Leentvaarkuijpers A, Coutinho RA, Brulein V, Safary A (1992) Simultaneous passive and active immunization against hepatitis A. Vaccine 10 (Suppl 1):138–141
23.
Zaaijer HL, Leentvaarkuijpers A, Rotman H, Lelie PN (1993) Hepatitis A antibody titres after infection and immunization—Implications for passive and active immunization. J Med Virol 40:22–27PubMed
24.
Wagner G, Lavanchy D, Darioli R, Pecoud A, Brulein V, Safary A, Frei PC (1993) Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine 11:1027–1032CrossRefPubMed
25.
Green MS, Cohen D, Lerman Y, Sjogren MH, Binn LN, Zur S, Slepon R, Robin G, Hoke CH, Bancroft WH, Safary A, Danon Y, Wiener M (1993) Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. J Infect Dis 168:740–743PubMed
26.
Goilav C, Zuckerman JN, Lafrenz M, Vidor E, Lauwers S, Ratheau C, Benichou G, Zuckerman AJ (1995) Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 46:287–292PubMed
27.
Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D (1997) The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15:1157–1161CrossRefPubMed
28.
Goubau P, Vangerven V, Safary A, Delem AD, Knops J, d’Hondt E, André FE, Desmyter J (1992) Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine 10 (Suppl 1):114–118
29.
Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, Lafaix C (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14:1132–1136CrossRefPubMed
30.
Linglof T, Van Hattum J, Kaplan KM, Corrigan J, Duval I, Jensen E, Kuter B (2001) An open study of subcutaneous administration of inactivated hepatitis A vaccine (Vaqta) in adults: safety, tolerability, and immunogenicity. Vaccine 19:3968–3971CrossRefPubMed
31.
Williams J, Fox-Leyva L, Christensen C, Fisher D, Schlicting E, Snowball M, Negus S, Mayers J, Koller R, Stout R (2000) Hepatitis A vaccine administration: comparison between ject-injector and needle injection. Vaccine 18:1939–1943CrossRefPubMed
32.
Brindle RJ, Morris CA, Berger R, Kurtz JB (1994) Inadequate response to intradermal hepatitis A vaccine. Vaccine 12:483–484CrossRefPubMed
33.
Dumas R, Forrat R, Lang J, Farinelli T, Loutan L (1997) Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine. Adv Therapy 14:160–167
34.
Beeching N, Clarke P, Kitchin N, Pirmohamed J, Veitch K, Weber F (2003) Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. J Travel Med (in press)
35.
Beran J, Chlibek R, Weber F (2003) A combined dual chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine 21:4650–4654CrossRefPubMed
36.
Zuckerman J, Peyron F, Wallon M, Gay F, Delolme H, Briantais P, Vidor E (1997) Comparison of the safety and immunogenicity of two inactivated hepatitis A vaccines. Adv Therapy 14:116–124
37.
Vidor E, Ratheau C, Briantais P, Vuillier D (1998) Comparison of two immunization schedules with an inactivated hepatitis A vaccine (Avaxim). J Travel Med 5:167–172PubMed
38.
Lolekha S, Pratuangtham S, Punpanich W, Bowonkiratikachorn P, Chimabutra K, Weber F (2003) Immunogenicity and safety of two doses of a pediatric hepatitis A vaccine in Thai children: comparison of 3 vaccination schedules (0–6, 0–12 or 0–18 Months). J Trop Ped 49:333–339
39.
Hornick R, Tucker R, Kaplan KM, Eves KA, Banerjee D, Jensen E, Kuter B (2001) A randomized study of a flexible booster dosing regimen of Vaqta in adults: safety, tolerability, and immunogenicity. Vaccine 19:4727–4731CrossRefPubMed
40.
Kanra G, Yalcin SS, Kara A, Ozmert E, Yurdakok K (2002) Hepatitis A booster vaccine in children after infant immunization. Ped Infect Dis J 21:727–730CrossRef
41.
Iwarson S, Lindh M (2002) Excellent booster response 4–6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 34:110–111CrossRefPubMed
42.
Kanra G, Yalcin SS, Ceyhan M, Yurdakok K (2000) Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk J Pediatr 42:105–108PubMed
43.
Landry P, Tremblay S, Darioli R, Genton B (2001) Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 19:399–402CrossRef
44.
Cederna JB, Klinzman D, Stapleton JT (1999) Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18:892–898CrossRefPubMed
45.
Zuckerman JN, Kirkpatrick CT, Huang M (1998) Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. J Travel Med 5:18–22PubMed
46.
Clarke P, Kitchin N, Souverbie F (2001) A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. Vaccine 19:4429–4433CrossRefPubMed
47.
Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, Spieker JM, De Medina M (2000) Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 19:743–750CrossRefPubMed
48.
Herzog C, Angst F, Beck BR, Bovier P, Farinelli T, Glueck R, Hatz C, Loutan L, Steffen R, Zellmeyer M (1997) Boosting healthy travelers with a virosome-formulated hepatitis A vaccine after basic immunization with an alum-adsorbed hepatitis A vaccine. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. 132
49.
Goilav C, Zuckerman J, Lafrenz M, Vidor E, Briantais P, Lauwers S, Ratheau C, Benichou G, Zuckerman A (1997) Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study. J Infect 34:158
50.
Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, Briantais Ph, Vidor E (2000) Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60:1–7CrossRefPubMed
51.
Werzberger A, Kuter B, Nalin D (1998) Six years’ follow-up after hepatitis A vaccination. N Engl J Med 338:1160CrossRef
52.
Maiwald H, Jilg W, Bock HL, Löscher T, Sonnenburg FV (1997) Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 15:346–348CrossRefPubMed
53.
Van Damme P, Thoelen S, Cramm M, Degroote K, Safary A, Meheus A (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44:446–451PubMed
54.
Wiedermann G, Kundi M, Ambrosch F (1998) Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0–6 schedule). Acta Trop 69:121–125CrossRefPubMed
55.
Van Herck K, Van Damme P (2001) Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 63:1–7CrossRefPubMed
56.
Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR (1996) Duration of protection from clinical hepatitis A disease after vaccination with Vaqta. J Med Virol 49:235–241CrossRefPubMed
57.
Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C (2002) Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68:489–493CrossRefPubMed
58.
Ashur Y, Adler R, Rowe M, Shouval D (1999) Comparison of immunogenicity of two hepatitis A vaccines—Vaqta® and Havrix®—in young adults. Vaccine 17:2290–2296CrossRefPubMed
59.
Braconier J, Wennerholm S, Norrby R (1999) Comparative immunogenicity and tolerance of Vaqta® and Havrix®. Vaccine 17:2181–2184CrossRefPubMed
60.
Bovier P, Althaus B, Glueck R, Chippaux A, Loutan L (1999) Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 6:228–233PubMed
61.
Williams J, Bruden D, Cagle H, McMahon B, Negus S, Christensen C, Snowball M, Bulkow L, Fox-Leyva L (2003) Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 21:3208–3211CrossRefPubMed
62.
Peetermans J (1992) Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 10 (Suppl 1):99–101
63.
Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA (1993) Development of the formalin-inactivated hepatitis A vaccine, Vaqta from the live attenuated virus strain CR326F. J Hepatol 18 (Suppl 2):20–26
64.
Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ (1992) Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90:2491–2495PubMed
65.
Winokur PL, Stapleton JT (1992) Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 14:580–586PubMed
66.
Vidor E, Xueref C, Blondeau C, Bajard A, Francon A, Goudeau A, Peyron F, Brasseur P, Zuckerman A (1996) Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. Biologicals 24:235–242CrossRefPubMed
67.
Centers for Disease Control and Prevention (1999) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48(RR-12):1–31
68.
Direction générale de la santé. Comité technique des vaccinations (1999) La vaccination contre l’hépatite A. In: Guide des vaccinations pp 99–103
69.
Lopez EL, Del Carmen X, Torrado LE, De Rosa MF, Gomez R, Dumas R, Wood SC, Contrini M (2001) Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 20:48–52CrossRefPubMed
70.
Dagan R, Greenberg D, Goldenbertg-Gehtman P, Vidor E, Briantais P, Pinsk V, Athias O, Dumas R (1999) Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17:1919–1925CrossRefPubMed
71.
Chadha MS, Chitambar SD, Shaikh NJ, Arankalle VA (1999) Exposure of Indian children to hepatitis A virus and vaccination age. Indian J Med Res 109:11–15PubMed
72.
Castillo de Febres C, Petrola C de, Escalona N de, Estopinan M, Bordones G, Zambrano B, Garcia A, Dumas R (2000) Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine 18:656–664CrossRef
73.
Lee CY, Huang LM, Lee PI, Chiu HH, Dumas R, Milcamps B, Lin W (2000) Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Southeast Asian J Trop Med Public Health 31:29–36PubMed
74.
Boutin JP, Buisson Y, Chapuis P, Delolme H, Germanetto P, Lamarque D, Lemardeley P, Lemoal JJ, Merouze F, Vidor E (1996) Evaluation of the safety and immunogenicity of a new inactivated hepatitis A vaccine in the French army. Int Rev Armed Forces Med Serv 69:249–254
75.
Vimolket T, Theamboonlers A, Dumas R, Milcamps B, Forrat R, Poovorawan Y (1998) Immunogenicity and safety of a new inactivated hepatitis A vaccine in Thai young adults. Southeast Asian J Trop Med Public Health 29:779–785PubMed
Metadata
Title
Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data
Authors
E. Vidor
R. Dumas
V. Porteret
F. Bailleux
K. Veitch
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2004
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-1094-0

Other articles of this Issue 4/2004

European Journal of Clinical Microbiology & Infectious Diseases 4/2004 Go to the issue

Announcements

April 2004

Article

Risk Factors For Mortality In Patients With Anaerobic Bacteremia

Review

Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Parasitic Infections

Brief Report

Failure of Broth-Based Tests to Detect Methicillin-Resistant Staphylococcus aureus in a Clinical Specimen

Review

Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious Diseases

Concise Article

Persistent Colonization of Nine Cystic Fibrosis Patients with an Achromobacter (Alcaligenes) xylosoxidans Clone

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits